IVIG vs SCIG vs fSCIG: which fits best?

The short answer

All three routes deliver the same fundamental therapy: pooled human immunoglobulin, restoring the antibody-fighting capacity that the immune system cannot make on its own. They differ in how the medication is given, how often, the steadiness of antibody levels, the time commitment per dose, the typical side-effect pattern, and what works best for a particular lifestyle.

There is no single right answer for every patient. The decision is shared between you and Dr. McNeil based on infection burden, IgG trough goals, lifestyle, comorbidities, prior tolerance, and insurance coverage.

What does each route actually look like?

IVIG — intravenous immunoglobulin

The medication is infused through an IV line, typically over 2 to 4 hours, every 3 to 4 weeks. Infusions take place at home with a visiting nurse, in the office’s co-located infusion suite at Horizon Infusions, or at a partner ambulatory infusion center. The patient relaxes during the infusion — reading, working, sleeping, or watching television.

Antibody pattern: A peak shortly after infusion, then a gradual decline over the dosing interval. Some patients experience a "wear-off" effect (more symptoms in the last few days before the next dose).

SCIG — subcutaneous immunoglobulin

The medication is administered under the skin with a small pump, typically once weekly (sometimes twice weekly). Each session takes 1 to 2 hours and is done at home by the patient. Multiple small-volume sites are used in the abdomen, thighs, or upper arms.

Antibody pattern: Steady-state troughs without large peaks or valleys. Many patients prefer this pattern because the “wear-off” effect is less pronounced.

fSCIG — facilitated subcutaneous immunoglobulin (HyQvia)

A single large-volume subcutaneous infusion, typically once monthly, delivered after a small dose of hyaluronidase that allows the tissue to absorb a much larger volume than traditional SCIG. Each session takes 1 to 2 hours and is done at home, similar to SCIG.

Antibody pattern: Closer to monthly IVIG dosing, but delivered subcutaneously at home.

Side-by-side comparison

How Dr. McNeil thinks through the decision

Several factors usually shape the choice:

• Infection burden and timing. A patient with breakthrough infections in the last days before each IVIG dose may benefit from the steadier levels of SCIG. A patient who does well on every-3-week IVIG and tolerates infusions has no reason to switch.
• IV access and infusion tolerance. Some patients have difficult IV access, post-infusion headaches, or fatigue that affects work. Subcutaneous routes avoid these issues entirely.
• Lifestyle and travel. Frequent travelers may prefer monthly dosing (IVIG or HyQvia) over weekly SCIG. Patients who prefer to stay home for treatment lean toward SCIG or HyQvia.
• Tolerance to local reactions. SCIG creates small local swelling at injection sites that resolves over hours to a day. Most patients tolerate this easily; some prefer to avoid it.
• Insurance and product coverage. Specific products are covered differently by different plans. The team navigates this in-house.
• Patient preference. Once the clinical factors are equal, what the patient wants matters — this is a lifelong therapy.

Can patients switch routes?

Yes. Many patients start on IVIG and switch to SCIG or fSCIG for steadier levels, easier home dosing, or lifestyle reasons. Others go the other direction — switching from weekly SCIG to monthly IVIG or HyQvia for less-frequent dosing. The transition is planned carefully to maintain therapeutic IgG levels through the change.

What about side effects?

All immunoglobulin replacement carries some risk of headache, body aches, fatigue, allergic reactions, and (rarely) more serious side effects. The risk profile differs slightly between routes:

• IVIG: Systemic side effects (headache, fatigue, body aches) are most common in the 24–48 hours after infusion. Premedication and slower infusion rates often help.
• SCIG: Local site reactions (swelling, redness, mild discomfort) are the most common — usually mild and resolving within hours. Systemic reactions are much less common.
• fSCIG (HyQvia): Larger local site reactions than SCIG (because of the larger volume), but typically still self-limited. Systemic reactions are uncommon.

Patients on Ig replacement are monitored over time, and the regimen is adjusted as needed.

Monitoring Ig replacement over time

Regardless of route, ongoing monitoring includes:

• IgG trough levels at intervals appropriate to the route
• Infection frequency, severity, and antibiotic use
• Pulmonary function and imaging where indicated (especially for patients with bronchiectasis)
• Watch for autoimmune or GI complications of underlying conditions like CVID
• Annual re-assessment of dose and route

Insurance and prior authorization

Immunoglobulin replacement is expensive and requires prior authorization from every insurance carrier. The office handles all prior authorizations in-house. Required documentation typically includes:

• Confirmed diagnosis (quantitative immunoglobulins, vaccine response, lymphocyte subsets)
• Documented history of infections that meet severity criteria
• Exclusion of secondary causes of low IgG
• Clinical justification for the proposed product and route

The team also coordinates with the specialty pharmacy and infusion partners to keep treatment on schedule.